Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces that three abstracts on aspects of the Company’s recently in-licensed compound from University College -London, QN-302, have been accepted as posters to be presented at the prestigious American Association of Cancer Research (AACR) conference in April. QN-302 (previously known as SOP1812) is the Company’s genomic quadruplex (G4)-selective transcription inhibitor platform being developed as a potential treatment for pancreatic ductal adenocarcinoma (PDAC), in addition to other tumors of high unmet clinical need.The three abstracts include:
Abstract Number: 2926
Title:  “Structure-based design of quadruplex-binding small molecule compounds: The essential role of water molecules”
Lead Author: Dr. Stephen Neidle
Session Title: Structural and Chemical Biology
Session Date and Time: Tuesday Apr 12, 2022 9:00 AM - 12:30 PM CDT
   
   
Abstract Number:  4069
Title:  “The potent quadruplex-binding compound SOP1812 shows anti-tumor activity in patient-derived in vivo models of pancreatic cancer”
Lead Author: Dr. Stephen Neidle
Session Title: New Chemotherapy Agents
Session Date and Time: Wednesday Apr 13, 2022 9:00 AM - 12:30 PM CDT
   
   
Abstract Number:  4068
Title:  “The potent quadruplex-binding compound SOP1812 shows potent anti-proliferative activity in a prostate cancer cell panel and anti-tumor activity in an in vivo model of metastatic prostate cancer”
Lead Author: Dr. Stephen Neidle
Session Title: New Chemotherapy Agents
Session Date and Time: Wednesday Apr 13, 2022 9:00 AM - 12:30 PM CDT
   

The AACR Conference, being held in New Orleans from April 8-13, 2022, is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.

About Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing treatments for cancer, as well as maintaining and expanding its core FDA-cleared FastPack® System, which has been used successfully in diagnostics for 20 years. Our investigational QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation. Our investigational QN-247 compound inhibits nucleolin, a key multi-functional regulatory protein that is overexpressed in cancer cells; QN-247 may be able to inhibit the cells’ proliferation. QN-247 has shown promise in preclinical studies for the treatment of acute myeloid leukemia (AML). The investigational compounds within Qualigen’s RAS-F family of RAS oncogene protein-protein interaction inhibitor small molecules are believed to inhibit or block the binding of mutated RAS genes’ proteins to their effector proteins, thereby leaving the proteins from the mutated RAS unable to cause further harm. In theory, such mechanism of action may be effective in the treatment of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers. In addition to its oncology drug pipeline, Qualigen has an established diagnostics business which manufactures and distributes proprietary and highly accurate rapid blood testing systems to physician offices and small hospitals for the management of prostate cancer and other diseases and health conditions.

For more information about Qualigen Therapeutics, Inc., please visit www.qualigeninc.com.

Forward-Looking Statements

This news release contains forward-looking statements by Qualigen that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. These statements include those related to the Company's prospects and strategy for the development of therapeutic drug candidates. Actual events or results may differ from the Company's expectations. For example, there can be no assurance that the Company will successfully develop any drugs (including QN-302, QN-247 and RAS-F); that preclinical development of the Company's drugs (including QN-302, QN-247 and RAS-F, and its deprioritized infectious-disease drug candidate QN-165) will be completed on any projected timeline or will be successful; that any clinical trials will be approved to begin by or will proceed as contemplated by any projected timeline, or at all; that any future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs will receive required regulatory approvals (or Fast Track designation or Orphan Drug status) or that they will be commercially successful; that patents will issue on the Company's owned and in-licensed patent applications; that such patents, if any, and the Company's currently owned and inlicensed patents would prevent competition; that the Company will be able to procure or earn sufficient working capital to complete the development, testing and launch of the Company's prospective therapeutic products (including QN-302, QN-247 and RAS-F, and QN-165); or that the Company will be able to maintain or expand market demand and/or market share for the Company's diagnostic products. The Company's stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company's business can be found in the Company's prior filings with the Securities and Exchange Commission, including its most recent Form 10-K, all of which are available at www.sec.gov.

The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor Relations:

David Kugelman Atlanta Capital Partners, LLC(404) 856-9157 or (866) 692-6847 Toll Free - U.S. & Canadadk@atlcp.com

Tony SchorInvestor Awareness, Inc.(847) 971-0922tony@investorawareness.com

Media:

Jules AbrahamJQA Partners, Inc.917-885-7378jabraham@jqapartners.com

Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Qualigen Therapeutics Charts.
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Qualigen Therapeutics Charts.